Prevention of Thrombocytopenia in Glioblastoma Patients

Exclusion Criteria

• •Concomitant radiotherapy (Romiplostim will be started after the completion of the RT/CT concomitant phase),
• •Other malignancies (prior hx malignancies),
• •Any anterior systemic chemotherapy,
• •Any known coagulation disease or known haematological disease even if resolved. Known hypercoagulate state (e.g., factor V Leiden, protein C defiency, protein S deficiency, PT 20201, antiphospholipid antibody syndrome…),
• •Prior Romiplostim exposure or prior exposure to other TPO mimetics,
• •History of thromboembolic disease \< 6 months. Treatment with anticoagulant such as Heparin or antivitamin K (LMWH as prophylactic treatment is authorized),
• •Any other hemato-toxicity (anemia, neutropenia) requiring EPO or GCSF,
• •Other causes of Temozolomide interruption (non haematological toxicities),
• •Known hypersensitivity to any E-coli derived product,
• •Participation to any other study during the last 30 days,
• •Refusal to give written informed consent,
• •Pregnancy or nursing,
• •For all men and women of childbearing potential: Refusal or inability to use effective means of contraception,
• •Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial,
• •Persons protected by a legal regime (guardianship, trusteeship),
• •Patients in emergency situations,
• •Patients kept in detention.